As per DelveInsight, the Acute Heart Failure Therapeutics Market scenario is expected to evolve in the coming years owing to ongoing Research and Development (R&D) activities and the active participation of the global pharma and biotech giants in the therapeutic segment.
DelveInsight’s “Acute Heart Failure Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute Heart Failure Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Acute Heart Failure market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Acute Heart Failure: An Overview
Heart Failure (HF), also known as congestive HF, is bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood).
Acute heart failure (AHF) is broadly defined as a rapid onset of new or worsening signs and symptoms of HF. It is often a potentially life-threatening condition requiring hospitalization, and emergency treatment aim to manage fluid overload and hemodynamic compromise. This umbrella term includes patients presenting for the first time with typical symptoms and signs of heart failure (de novo AHF) and those with worsening their pre-existing cardiomyopathy (acute decompensated heart failure).
Acute Heart Failure Market Key Facts
As per the study by Farmakis et al. (2017), Acute Heart Failure constitutes the first reason for hospital admission in the elderly, with a total of approximately one million admissions per year in the US and a similar number in Europe.
According to the study conducted by Blair et al. (2013), in the US, the incidence of the first hospitalization for AHF approaches 400 per 100,000 population and approaches 1,000 per 100,000 population for the second hospitalization.
The study by Kurmani et al. (2017) found that 20–30% of patients with ADHF had an element of renal dysfunction, and 40% had diabetes mellitus.
Acute Heart Failure Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Acute Heart Failure market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Acute Heart Failure market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Acute Heart Failure Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Acute Heart Failure (AHF) Epidemiology Segmentation
Total Incident Cases of Acute Heart Failure (AHF)
Gender-specific Incident Cases of Acute Heart Failure (AHF)
Incident cases of Acute Heart Failure (AHF) with Ejection Fraction
Incident cases of Acute Heart Failure (AHF) associated with comorbidities [e.g., diabetes mellitus, renal dysfunction, and others]
Acute Heart Failure Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Heart Failure market or expected to be launched during the study period. The analysis covers Acute Heart Failure market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Acute Heart Failure Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/acute-heart-failure-ahf-market
Some of the key players involved in developing therapies for Acute Heart Failure (AHF) include:
Boehringer Ingelheim
Eli Lilly and Company
Windtree Therapeutics
Arena Pharmaceuticals
And many others.
Acute Heart failure (AHF) Therapies covered in the report includes:
Empagliflozin
Istaroxime
APD418
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/acute-heart-failure-ahf-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Acute Heart Failure Competitive Intelligence Analysis
4. Acute Heart Failure Market Overview at a Glance
5. Acute Heart Failure Disease Background and Overview
6. Acute Heart Failure Patient Journey
7. Acute Heart Failure Epidemiology and Patient Population
8. Acute Heart Failure Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Heart Failure Unmet Needs
10. Key Endpoints of Acute Heart Failure Treatment
11. Acute Heart Failure Marketed Products
12. Acute Heart Failure Emerging Therapies
13. Acute Heart Failure Seven Major Market Analysis
14. Attribute Analysis
15. Acute Heart Failure Market Outlook (7 major markets)
16. Acute Heart Failure Access and Reimbursement Overview
17. KOL Views on the Acute Heart Failure Market.
18. Acute Heart Failure Market Drivers
19. Acute Heart Failure Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/acute-heart-failure-ahf-market
About DelveInsightDelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Childhood Atropine For Myopia Progression Market“Childhood Atropine For Myopia Progression Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Childhood Atropine For Myopia Progression Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
